Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg

NCT02024152 | Completed Phase 1

• 1 other identifier: ETTAU-01 (CTN-P0-741)
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This study is to investigate the pharmacokinetics (PK) together with the safety and tolerability of JDP-205 at 5 mg and 10 mg intravenous doses and 10 mg intramuscular dose, in comparison to the marketed cetirizine oral product Zyrtec® 10 mg tablets (an OTC product) in healthy male and female volunteers after a single dose administration.

Conditions

Acute Urticaria

Outcome Measures

Primary Outcomes (2)

• Difference in pharmacokinetics: Difference in AUC

  36 hours post dose

• Differences in pharmacokinetics: difference in Cmax

  36 hours pose dose

Study Arms (4)

JDP-205 IV high dose

EXPERIMENTAL

Drug: JDP-205 IV high dose; Drug: JDP-205 IV low dose; Drug: JDP-205 IM

JDP-205 IV low dose

EXPERIMENTAL

Drug: JDP-205 IV high dose; Drug: JDP-205 IV low dose; Drug: JDP-205 IM

JDP-205 IM high dose

EXPERIMENTAL

Drug: JDP-205 IV high dose; Drug: JDP-205 IV low dose; Drug: JDP-205 IM

Control

ACTIVE COMPARATOR

Drug: Control: Zyrtec

Interventions

JDP-205 IV high dose DRUG

JDP-205 IM high dose; JDP-205 IV high dose; JDP-205 IV low dose

JDP-205 IV low dose DRUG

JDP-205 IM high dose; JDP-205 IV high dose; JDP-205 IV low dose

JDP-205 IM DRUG

JDP-205 IM high dose; JDP-205 IV high dose; JDP-205 IV low dose

Control: Zyrtec DRUG

Control

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female volunteer
• Volunteer aged of at least 18 years
• Volunteer with a body mass index (BMI) greater than or equal to 18.50 and below 30.00 kg/m2
• Non- or ex-smokers; an ex-smoker being defined as someone who completely stopped smoking for at least 12 months before day 1 of this study.
• Availability for the entire study period
• Motivated volunteer and absence of intellectual problems likely to limit the validity of consent to participate in the study or the compliance with protocol requirements; ability to cooperate adequately; ability to understand and observe the instructions of the physician or designee
• Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance
• Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on physical examination (including the examination of the anterolateral thigh muscles) and/or clinical laboratory evaluations (hematology, biochemistry, ECG and urinalysis)
• Willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer

You may not qualify if:

• Females who are pregnant or are lactating
• Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the entire duration of the study (from the screening visit until study completion)
• History of significant hypersensitivity to cetirizine or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs
• Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects
• History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability
• Presence of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease
• Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases
• Presence of out-of-range cardiac interval (PR \< 110 msec, PR \> 200 msec, QRS \< 60 msec, QRS \>110 msec and QTc \> 440 msec) on the screening ECG or other clinically significant ECG abnormalities
• Known presence of rare hereditary problems of galactose and /or lactose intolerance
• Maintenance therapy with any drug, or significant history of drug dependency or alcohol abuse (\> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)
• Any clinically significant illness in the previous 28 days before day 1 of this study
• Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450 (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin, fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and St John's Wort), in the previous 28 days before day 1 of this study
• Use of antihistaminic medication in the previous 7 days before day 1 of this study
• Any history of tuberculosis and/or prophylaxis for tuberculosis
• Positive urine screening of ethanol and/or drugs of abuse

Sponsors & Collaborators

• JDP Therapeutics, Inc.: lead
• Algorithme Pharma Inc: collaborator

Study Sites (1)

Algorithme Pharma

Montreal, Quebec, Canada

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 18, 2013
• First Posted: December 31, 2013
• Study Start: March 1, 2011
• Primary Completion: July 1, 2011
• Study Completion: July 1, 2011
• Last Updated: March 6, 2024

Record last verified: 2024-03

Locations

CA (1)